Coronavirus diseases 2019 : Current biological situation and potential therapeutic perspective
Copyright © 2020 Elsevier B.V. All rights reserved..
Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at the end of December 2019. SARS-CoV-2 is a highly pathogenic zoonotic virus and closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a global pandemic due to its high infectiousness, and worldwide morbidities and mortalities. The Chinese scientists at the start of the outbreak reported genome sequences, which made the characterization of glycoproteins and other structural proteins possible. Moreover, researchers across the world have widely focused on understanding basic biology, developing vaccines, and therapeutic drugs against the COVID-19. However, until now, no promising treatment options, as well as vaccines, are available. In this review, we have described SARS-CoV-2's genome, transmission, and pathogenicity. We also discussed novel potential therapeutic agents that can help to treat the COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:886 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 886(2020) vom: 05. Nov., Seite 173447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Suliman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 26.10.2020 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2020.173447 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313383731 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313383731 | ||
| 003 | DE-627 | ||
| 005 | 20231225150446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2020.173447 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313383731 | ||
| 035 | |a (NLM)32763302 | ||
| 035 | |a (PII)S0014-2999(20)30539-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Suliman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coronavirus diseases 2019 |b Current biological situation and potential therapeutic perspective |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2020 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at the end of December 2019. SARS-CoV-2 is a highly pathogenic zoonotic virus and closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a global pandemic due to its high infectiousness, and worldwide morbidities and mortalities. The Chinese scientists at the start of the outbreak reported genome sequences, which made the characterization of glycoproteins and other structural proteins possible. Moreover, researchers across the world have widely focused on understanding basic biology, developing vaccines, and therapeutic drugs against the COVID-19. However, until now, no promising treatment options, as well as vaccines, are available. In this review, we have described SARS-CoV-2's genome, transmission, and pathogenicity. We also discussed novel potential therapeutic agents that can help to treat the COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pathogenicity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Tombuloglu, Huseyin |e verfasserin |4 aut | |
| 700 | 1 | |a Hassanein, Sameh E |e verfasserin |4 aut | |
| 700 | 1 | |a Rehman, Suriya |e verfasserin |4 aut | |
| 700 | 1 | |a Bozkurt, Ayhan |e verfasserin |4 aut | |
| 700 | 1 | |a Cevik, Emre |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Ghany, Shaimaa |e verfasserin |4 aut | |
| 700 | 1 | |a Nabi, Ghulam |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Ashaq |e verfasserin |4 aut | |
| 700 | 1 | |a Sabit, Hussein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 886(2020) vom: 05. Nov., Seite 173447 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:886 |g year:2020 |g day:05 |g month:11 |g pages:173447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2020.173447 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 886 |j 2020 |b 05 |c 11 |h 173447 | ||